| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7855211 | ELI LILLY AND CO | Protein kinase inhibitors |
Dec, 2029
(5 years from now) | |
Verzenio is owned by Eli Lilly And Co.
Verzenio contains Abemaciclib.
Verzenio has a total of 1 drug patent out of which 0 drug patents have expired.
Verzenio was authorised for market use on 28 September, 2017.
Verzenio is available in tablet;oral dosage forms.
Verzenio can be used as as monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
Drug patent challenges can be filed against Verzenio from 28 September, 2021.
The generics of Verzenio are possible to be released after 15 December, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 12, 2024 |
| New Indication(I-877) | Oct 12, 2024 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2022 |
| New Indication(I-768) | Feb 26, 2021 |
Drugs and Companies using ABEMACICLIB ingredient
NCE-1 date: 28 September, 2021
Market Authorisation Date: 28 September, 2017
Treatment: As monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the...
Dosage: TABLET;ORAL
VERZENIO family patents
